Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion type Assertion NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_head.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion description "[Similarly, patients with these genotypes (GSTP1*I/V and GSTP1*V/V) also had an increased risk of GI toxicity when treated with an initial pulsed high-dose CTX regimen (OR 3.33, 95% CI 1.03, 10.79).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_provenance.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion evidence source_evidence_literature NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_provenance.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion SIO_000772 16995867 NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_provenance.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion wasDerivedFrom befree-20140225 NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_provenance.
- NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_assertion wasGeneratedBy ECO_0000203 NP166826.RAAMfAaEB1ZhvRKjq8QTUNOvirvtzdKSs8fax-E5CqPME130_provenance.